drugset / Trial / NCT06496789

Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

NCT06496789

NaSingle-groupOpen-labelTreatment

Summary

evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Timeline

Start
2023-05-27
Primary completion
2024-12-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Serplulimab Monoclonal antibody
Background Oxaliplatin Small molecule
Background Serplulimab Monoclonal antibody